Insmed, Inc. (NASDAQ:INSM) Receives $205.52 Consensus Price Target from Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have been given an average rating of “Buy” by the twenty-five research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twenty-two have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $205.5217.

Several analysts have recently weighed in on INSM shares. Mizuho set a $192.00 price target on shares of Insmed in a research note on Tuesday, June 16th. UBS Group reaffirmed a “buy” rating and set a $172.00 price target on shares of Insmed in a research report on Friday, August 7th. Royal Bank Of Canada decreased their price objective on Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $235.00 price objective on shares of Insmed in a research report on Tuesday, July 28th. Finally, BMO Capital Markets began coverage on Insmed in a research note on Monday, July 20th. They set an “outperform” rating and a $192.00 target price for the company.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 21,398 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the completion of the transaction, the chief executive officer directly owned 258,917 shares in the company, valued at approximately $26,751,304.44. This represents a 7.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 273,753 shares of company stock worth $35,604,764. 2.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently made changes to their positions in INSM. iA Global Asset Management Inc. increased its holdings in shares of Insmed by 15,973.5% in the 4th quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock valued at $4,644,000 after acquiring an additional 26,516 shares during the last quarter. Monashee Investment Management LLC purchased a new stake in Insmed during the fourth quarter worth approximately $8,702,000. Danske Bank A S boosted its holdings in Insmed by 4,494.1% in the fourth quarter. Danske Bank A S now owns 110,258 shares of the biopharmaceutical company’s stock valued at $19,189,000 after purchasing an additional 107,858 shares in the last quarter. PKO Investment Management Joint Stock Co acquired a new position in Insmed in the fourth quarter valued at approximately $1,967,000. Finally, SBI Okasan Asset Management Co.Ltd. purchased a new position in Insmed in the fourth quarter valued at approximately $3,562,000.

Insmed Price Performance

NASDAQ INSM opened at $126.29 on Monday. Insmed has a 52 week low of $90.39 and a 52 week high of $212.75. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. The business’s fifty day simple moving average is $115.86 and its 200-day simple moving average is $125.06. The firm has a market cap of $27.58 billion, a PE ratio of -30.73 and a beta of 0.82.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm had revenue of $425.49 million during the quarter, compared to analyst estimates of $395.50 million. During the same quarter in the prior year, the firm posted ($1.70) earnings per share. Insmed’s quarterly revenue was up 296.1% on a year-over-year basis. As a group, equities analysts anticipate that Insmed will post -1.83 earnings per share for the current year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.